Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study
Systemic sclerosis, a severe inflammatory autoimmune disease, shares a common thread with cancer through the underlying mechanism of inflammation. This inflammatory milieu not only drives the immune dysregulation characteristic of autoimmune diseases but also plays a pivotal role in the pathogenesis of cancer. Among the cellular components involved, B cells have emerged as key players in hematologic tumor and autoimmune disease, contributing to immune dysregulation and persistent tissue fibrosis in systemic sclerosis, as well as tumor progression and immune evasion in cancer.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Marion Subklewe, Giulia Magno, Christina Gebhardt, Veit B ücklein, Franziska Szelinski, Héctor Julián Rincón Arévalo, Hanel Gerulf Hänel, Thomas Dörner, Gerhard Zugmaier, Michael von Bergwelt-Baildon, Alla Skapenko, Hendrik Schulze-Koops Tags: Original Research Source Type: research